Trial Profile
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia (AML) After Allogeneic Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2018
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 29 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 29 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 18 Feb 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.